<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03457701</url>
  </required_header>
  <id_info>
    <org_study_id>201771</org_study_id>
    <nct_id>NCT03457701</nct_id>
  </id_info>
  <brief_title>Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)</brief_title>
  <official_title>A Repeat Dose, Open Label, Two Period, Randomized, Cross Over Study to Compare the Effect of Daprodustat to Recombinant, Human Erythropoietin (rhEPO) on Oral Iron Absorption in Adult Participants With Anemia Associated With Chronic Kidney Disease Who Are Not on Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Daprodustat administration has the potential, by virtue of increasing hypoxia-inducible&#xD;
      factor (HIF) levels, to increase oral iron absorption and incorporation into hemoglobin&#xD;
      (Hgb). Therefore, the purpose of this study is to compare the effect of daprodustat to rhEPO&#xD;
      (i.e., epoetin alfa or darbepoetin alfa) on non-heme oral iron absorption using stable&#xD;
      isotopic iron (57Fe and 58Fe) by measuring incorporation of iron in erythrocytes. This study&#xD;
      will be a randomized, repeat dose, open label, two period cross-over study in adult, male and&#xD;
      female participants with anemia associated with chronic kidney disease who are not on&#xD;
      dialysis currently treated with stable doses less than or equal to (&lt;=) 50 percent (%) change&#xD;
      in 4-weekly dose) for at least 8 weeks prior to and including the screening period, of rhEPO&#xD;
      (i.e., epoetin alfa or darbepoetin alfa). Sufficient participants will be enrolled such that&#xD;
      at least 12 participants comprise the Evaluable Population. The study will compare the&#xD;
      fractional iron absorption between treatment arms (daprodustat and rhEPO [i.e., epoetin alfa&#xD;
      or darbepoetin alfa]) and will evaluate the difference is equal/not equal to zero.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">June 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 3, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly assigned either to remain on their current therapy (either epoetin alfa or darbepoetin alfa) or be switched to daprodustat in either of the treatment periods.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an Open-label study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of iron absorbed</measure>
    <time_frame>Up to Day 57</time_frame>
    <description>Venous blood samples will be collected for measurement of erythrocyte isotopic iron content to compare the efficacy of daprodustat to rhEPO (i.e., epoetin alfa or darbepoetin alfa) on iron absorption on Days 29 and 57.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in serum iron at Day 14</measure>
    <time_frame>Baseline (Day 1) and Day 14</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on serum iron.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in serum iron at Day 28</measure>
    <time_frame>Baseline (Day 1) and Day 28</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on serum iron.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in transferrin at Day 14</measure>
    <time_frame>Baseline (Day 1) and Day 14</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on transferrin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in transferrin at Day 28</measure>
    <time_frame>Baseline (Day 1) and Day 28</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on transferrin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in transferrin saturation at Day 14</measure>
    <time_frame>Baseline (Day 1) and Day 14</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on transferrin saturation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in transferrin saturation at Day 28</measure>
    <time_frame>Baseline (Day 1) and Day 28</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on transferrin saturation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in soluble transferrin receptor at Day 14</measure>
    <time_frame>Baseline (Day 1) and Day 14</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on soluble transferrin receptor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in soluble transferrin receptor at Day 28</measure>
    <time_frame>Baseline (Day 1) and Day 28</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on soluble transferrin receptor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ferritin at Day 14</measure>
    <time_frame>Baseline (Day 1) and Day 14</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on ferritin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ferritin at Day 28</measure>
    <time_frame>Baseline (Day 1) and Day 28</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on ferritin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in hepcidin at Day 14</measure>
    <time_frame>Baseline (Day 1) and Day 14</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on hepcidin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in hepcidin at Day 28</measure>
    <time_frame>Baseline (Day 1) and Day 28</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on hepcidin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in erythroferrone at Day 14</measure>
    <time_frame>Baseline (Day 1) and Day 14</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on erythroferrone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in erythroferrone at Day 28</measure>
    <time_frame>Baseline (Day 1) and Day 28</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on erythroferrone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hgb at Day 14</measure>
    <time_frame>Baseline (Day 1) and Day 14</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on Hgb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hgb at Day 28</measure>
    <time_frame>Baseline (Day 1) and Day 28</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on Hgb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in hematocrit at Day 14</measure>
    <time_frame>Baseline (Day 1) and Day 14</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on hematocrit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in hematocrit at Day 28</measure>
    <time_frame>Baseline (Day 1) and Day 28</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on hematocrit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in red blood cell number at Day 14</measure>
    <time_frame>Baseline (Day 1) and Day 14</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on red blood cell number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in red blood cell number at Day 28</measure>
    <time_frame>Baseline (Day 1 and Day 28</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on red blood cell number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in mean corpuscular volume at Day 14</measure>
    <time_frame>Baseline (Day 1) and Day 14</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on mean corpuscular volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in mean corpuscular volume at Day 28</measure>
    <time_frame>Baseline (Day 1) and Day 28</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on mean corpuscular volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in reticulocyte Hgb at Day 14</measure>
    <time_frame>Baseline (Day 1) and Day 14</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on reticulocyte Hgb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in reticulocyte Hgb at Day 28</measure>
    <time_frame>Baseline (Day 1) and Day 28</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on reticulocyte Hgb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in reticulocyte number at Day 14</measure>
    <time_frame>Baseline (Day 1) and Day 14</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on reticulocyte number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in reticulocyte number at Day 28</measure>
    <time_frame>Baseline (Day 1) and Day 28</time_frame>
    <description>Blood samples will be collected to characterize the effect of daprodustat or rhEPO on reticulocyte number.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with any adverse event (AE)</measure>
    <time_frame>Up to 73 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with any AE by severity</measure>
    <time_frame>Up to 73 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with any serious AE (SAE)</measure>
    <time_frame>Up to 73 days</time_frame>
    <description>A SAE is defined as any untoward medical occurrence that, at any dose may result in death, is life-threatening, may require inpatient hospitalization or prolongation of existing hospitalization, result in persistent disability/incapacity, or may lead to any congenital anomaly or birth defect.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with any SAE by severity</measure>
    <time_frame>Up to 73 days</time_frame>
    <description>A SAE is defined as any untoward medical occurrence that, at any dose may result in death, is life-threatening, may require inpatient hospitalization or prolongation of existing hospitalization, result in persistent disability/incapacity, or may lead to any congenital anomaly or birth defect.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants discontinued the study medication due to AE</measure>
    <time_frame>Up to 73 days</time_frame>
    <description>Number of participants discontinuing study medication due to adverse event will be analyzed</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with abnormal systolic blood pressure assessment (SBP) and diastolic blood pressure (DBP)</measure>
    <time_frame>Up to 73 days</time_frame>
    <description>Systolic and diastolic blood pressure will be measured in seated position with a completely automated device. Measurements will be preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with abnormal pulse rate</measure>
    <time_frame>Up to 73 days</time_frame>
    <description>Pulse rate will be measured in seated position with a completely automated device. Measurements will be preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with abnormal oral temperature</measure>
    <time_frame>Up to 73 days</time_frame>
    <description>Number of participants with abnormal oral temperature will be evaluated.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with abnormal respiratory rate</measure>
    <time_frame>Up to 73 days</time_frame>
    <description>Number of participants with abnormal respiratory rate will be evaluated.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Anaemia</condition>
  <arm_group>
    <arm_group_label>rhEPO+57Fe followed by Daprodustat+58Fe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomly assigned to remain on their current therapy (either epoetin alfa or darbepoetin alfa) in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (57Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive Daprodustat in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (58Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: Histamine [H2] receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhEPO+58Fe followed by Daprodustat+57Fe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomly assigned to remain on their current therapy (either epoetin alfa or darbepoetin alfa) in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (58Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive Daprodustat in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (57Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daprodustat+57Fe followed by rhEPO+58Fe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomly assigned to receive Daprodustat in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (57Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive rhEPO (either epoetin alfa or darbepoetin alfa) in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (58Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daprodustat+58Fe followed by rhEPO+57Fe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomly assigned to receive Daprodustat in Treatment Period 1. For assessment of incorporation of iron into erythrocytes, participants will be administered ferrous sulfate containing a stable isotope of iron (58Fe) orally in a randomized fashion following 2 weeks of administration of randomized study treatment. At Day 29 participants will be crossed over to receive rhEPO (either epoetin alfa or darbepoetin alfa) in Treatment Period 2. At 2 weeks following initiation of dosing in Treatment Period 2, participants will again be administered ferrous sulfate containing the stable iron isotope (57Fe) orally. Participants will be advised to maintain use of oral iron supplementation (except ferric citrate) and acid-reducing agents (example: H2 receptor antagonists, proton pump inhibitors, antacids) at a consistent dosage and frequency.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daprodustat</intervention_name>
    <description>Daprodustat will be available as 1 milligram (mg), 2 mg and 4 mg tablets strengths. One tablet to be taken daily without regard for food.</description>
    <arm_group_label>Daprodustat+57Fe followed by rhEPO+58Fe</arm_group_label>
    <arm_group_label>Daprodustat+58Fe followed by rhEPO+57Fe</arm_group_label>
    <arm_group_label>rhEPO+57Fe followed by Daprodustat+58Fe</arm_group_label>
    <arm_group_label>rhEPO+58Fe followed by Daprodustat+57Fe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhEPO</intervention_name>
    <description>rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.</description>
    <arm_group_label>Daprodustat+57Fe followed by rhEPO+58Fe</arm_group_label>
    <arm_group_label>Daprodustat+58Fe followed by rhEPO+57Fe</arm_group_label>
    <arm_group_label>rhEPO+57Fe followed by Daprodustat+58Fe</arm_group_label>
    <arm_group_label>rhEPO+58Fe followed by Daprodustat+57Fe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous sulfate containing the stable iron isotope (57Fe)</intervention_name>
    <description>57Fe will be available in oral solution. An oral solution will be administered containing 10 mg of 57Fe as ferrous sulfate.</description>
    <arm_group_label>Daprodustat+57Fe followed by rhEPO+58Fe</arm_group_label>
    <arm_group_label>Daprodustat+58Fe followed by rhEPO+57Fe</arm_group_label>
    <arm_group_label>rhEPO+57Fe followed by Daprodustat+58Fe</arm_group_label>
    <arm_group_label>rhEPO+58Fe followed by Daprodustat+57Fe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous sulfate containing the stable iron isotope (58Fe)</intervention_name>
    <description>58Fe will be available in oral solution. An oral solution will be administered containing 3 mg of 58Fe as ferrous sulfate with 7 mg of 56Fe as ferrous sulfate (natural abundance Fe).</description>
    <arm_group_label>Daprodustat+57Fe followed by rhEPO+58Fe</arm_group_label>
    <arm_group_label>Daprodustat+58Fe followed by rhEPO+57Fe</arm_group_label>
    <arm_group_label>rhEPO+57Fe followed by Daprodustat+58Fe</arm_group_label>
    <arm_group_label>rhEPO+58Fe followed by Daprodustat+57Fe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be at least 18 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Participants who are Stage 3, 4 or 5 Chronic kidney disease (CKD) (confirmed at Week-4&#xD;
             only) defined by estimated glomerular filtration rate (eGFR) using the CKD&#xD;
             Epidemiology Collaboration (CKD-EPI) formula.&#xD;
&#xD;
          -  Participants who are currently treated with stable doses (&lt;=50% change in 4-weekly&#xD;
             dose) for at least 8 weeks prior to and including the screening period, of rhEPO&#xD;
             (i.e., epoetin alfa or darbepoetin alfa).&#xD;
&#xD;
          -  Participants with Hgb levels between 9.0 and 11.5 g/dL, inclusive, who meet the Hgb&#xD;
             stability criteria.&#xD;
&#xD;
          -  Participants may be on stable maintenance oral iron supplementation (less than [&lt;] 50%&#xD;
             change in overall dose and compliance of 80% of prescribed doses in the 4 weeks prior&#xD;
             to and including the screening period). If participants have been on intravenous (IV)&#xD;
             iron, then participants will not have received IV iron for 8 weeks prior to the Day 1&#xD;
             visit.&#xD;
&#xD;
          -  Male or Female participants may participate. A female participant is eligible to&#xD;
             participate if she is not pregnant, not breastfeeding, and at least one of the&#xD;
             following conditions applies: not a woman of childbearing potential (WOCBP), or a&#xD;
             WOCBP who agrees to follow the contraceptive guidance during the treatment period to&#xD;
             the follow-up visit.&#xD;
&#xD;
          -  Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  On dialysis or clinical evidence of impending need to initiate dialysis within 90 days&#xD;
             after study start (i.e., Day 1).&#xD;
&#xD;
          -  Planned kidney transplant within 3 months after study start.&#xD;
&#xD;
          -  A positive test for Human Immunodeficiency Virus (HIV) antibody.&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions or hypersensitivity to excipients&#xD;
             in the investigational products&#xD;
&#xD;
          -  Use of any prescription or non-prescription drugs or dietary supplements that are&#xD;
             prohibited from screening until the end of Treatment Period 2.&#xD;
&#xD;
          -  Planned or current administration of methoxy polyethylene glycol (PEG)-epoetin beta.&#xD;
&#xD;
          -  The participant has participated in a clinical trial and has received an experimental&#xD;
             investigational product within the prior 30 days or 5 half lives, whichever is longer,&#xD;
             from screening through Day 1.&#xD;
&#xD;
          -  At or below the lower limit of the reference range at screening for Vitamin B12 (may&#xD;
             rescreen in a minimum of 8 weeks).&#xD;
&#xD;
          -  Ferritin outside the range between 100 and 500 nanogram per milliliter (ng/mL),&#xD;
             inclusive, at screening.&#xD;
&#xD;
          -  Transferrin saturation (TSAT) outside the range between 15% and 40%, inclusive, at&#xD;
             Screening.&#xD;
&#xD;
          -  Folate &lt; 2.0 ng/mL (4.5 nanomoles per liter [nmol/L]; may rescreen in a minimum of 8&#xD;
             weeks) at screening.&#xD;
&#xD;
          -  High sensitivity C-reactive protein (hsCRP) &gt;=20 microgram per milliliter (Î¼g/mL) at&#xD;
             screening.&#xD;
&#xD;
          -  Myocardial infarction or acute coronary syndrome: &lt;=8 weeks prior to screening through&#xD;
             Day 1.&#xD;
&#xD;
          -  Hospitalization for greater than 24 hours: &lt;=8 weeks prior to screening through Day 1&#xD;
&#xD;
          -  Stroke or transient ischemic attack &lt;=8 weeks prior to screening through Day 1.&#xD;
&#xD;
          -  Class IV heart failure, as defined by the New York Heart Association (NYHA) functional&#xD;
             classification system.&#xD;
&#xD;
          -  Current uncontrolled hypertension as determined by the investigator.&#xD;
&#xD;
          -  QT interval corrected for heart rate using Bazett's formula (QTcB): QTcB &gt;500&#xD;
             milliseconds (msec), or QTcB &gt; 530 msec in participants with Bundle Branch Block.&#xD;
             There is no corrected QT interval (QTc) exclusion for participants with a&#xD;
             predominantly paced rhythm.&#xD;
&#xD;
          -  Active chronic inflammatory disease that could impact erythropoiesis.&#xD;
&#xD;
          -  History of bone marrow aplasia or pure red cell aplasia.&#xD;
&#xD;
          -  Conditions, other than anemia associated with chronic kidney disease, which can affect&#xD;
             erythropoiesis.&#xD;
&#xD;
          -  Evidence of actively bleeding gastric, duodenal, or esophageal ulcer disease OR&#xD;
             clinically significant gastrointestinal (GI) bleeding from &lt;=4 weeks prior to&#xD;
             screening through Day 1.&#xD;
&#xD;
          -  Liver disease (any of the following): Alanine transaminase (ALT) &gt;2 times upper limit&#xD;
             of normal (ULN; screening only); Bilirubin &gt;1.5 times ULN (screening only). Current or&#xD;
             chronic history of liver disease, or known hepatic or biliary abnormalities (with the&#xD;
             exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  Major surgery (excluding vascular access surgery) within the 8 weeks prior to&#xD;
             screening through Day 1, or planned during the study.&#xD;
&#xD;
          -  Blood transfusion within 8 weeks prior to screening through Day 1, or an anticipated&#xD;
             need for blood transfusion during the study.&#xD;
&#xD;
          -  Clinical evidence of an acute infection, or history of infection requiring IV&#xD;
             antibiotic therapy from 4 weeks prior to screening through Day 1.&#xD;
&#xD;
          -  History of malignancy within the two years prior to screening through Day 1 or&#xD;
             currently receiving treatment for cancer, with the exception of localized squamous&#xD;
             cell or basal cell carcinoma of the skin definitively treated 12 weeks prior to Day 1.&#xD;
&#xD;
          -  Any other condition, clinical or laboratory abnormality, or examination finding that&#xD;
             the investigator considers would put the participant at unacceptable risk, which may&#xD;
             affect study compliance or prevent understanding of the aims or investigational&#xD;
             procedures or possible consequences of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bernard Fischbach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Saravanan Balamuthusamy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lufkin</city>
        <state>Texas</state>
        <zip>75904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Pablo Pergola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eric J Lawitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recombinant human erythropoietin</keyword>
  <keyword>Anemia</keyword>
  <keyword>Daprodustat</keyword>
  <keyword>Chronic kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months .</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

